• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

SynAct Pharma

14.50 SEK

-0.28 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.28 %
-2.42 %
-20.07 %
-35.84 %
-31.92 %
-14.71 %
-79.82 %
-84.69 %
+214.56 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
815.1M SEK
Turnover
4.53M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8.
2026

Interim report Q2'26

3.11.
2026

Interim report Q3'26

18.2.
2027

Annual report '26

Press release16 hours ago

SynAct obtains key US patent for resomelagon securing exclusivity until 2044

SynAct Pharma
Regulatory press releaseyesterday

Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)

SynAct Pharma
Press release5/28/2026, 4:34 PM

Redeye: SynAct (Q1 Update): ADVANCE Topline in June

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/27/2026, 5:30 AM

SynAct Pharma publishes Q1 2026 interim results

SynAct Pharma
Press release5/26/2026, 6:58 AM

Synact Pharma large shareholder trading update

SynAct Pharma
Press release5/19/2026, 12:00 PM

SynAct Pharma to present at the BioStock Global Forum 2026 on May 21

SynAct Pharma
Regulatory press release5/7/2026, 8:00 AM

Notice of annual general meeting in SynAct Pharma AB

SynAct Pharma
Press release5/6/2026, 9:29 AM

BioStock: SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

SynAct Pharma
Press release5/6/2026, 5:00 AM

SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study

SynAct Pharma
Press release5/5/2026, 9:30 AM

SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen

SynAct Pharma
Press release4/27/2026, 7:07 AM

BioStock: What good data looks like: SynAct Pharma ahead of its ADVANCE readout

SynAct Pharma
Regulatory press release4/23/2026, 5:00 PM

SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting

SynAct Pharma
Regulatory press release4/15/2026, 4:00 PM

SynAct Pharma publishes Annual Report 2025

SynAct Pharma
Regulatory press release3/31/2026, 8:00 AM

Change in number of shares and voting rights in Synact Pharma AB

SynAct Pharma
Press release3/26/2026, 1:30 PM

SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon

SynAct Pharma
Press release3/18/2026, 8:11 AM

BioStock: SynAct Pharma lays out dual strategy for resolution therapy at capital markets day

SynAct Pharma
Press release3/18/2026, 7:00 AM

SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25

SynAct Pharma
Press release3/4/2026, 11:00 AM

Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11

SynAct Pharma
Third party research3/4/2026, 6:27 AM

Synact Pharma: Multiple shots on goal in 2026 for resomelagon - Edison

SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment completed in February 2026 (n=246), top-line...

SynAct Pharma
Press release3/3/2026, 3:25 PM

Redeye: SynAct Pharma: Interview about the directed share issue

SynAct Pharma